Skip to main content
OpenTrials
Completed

NCT Number: NCT01050140

The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men

Dietary consumption of fructose has increased by nearly 50% since 1960.

A high fructose diet (HFrD) results in greater visceral adiposity and systemic insulin resistance than a high glucose diet. The effects of fructose on liver fatty acid and ATP stores, systemic oxidative stress and cardiovascular status are not fully known.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

School of Biomedical Sciences, University of Nottingham

Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

About this study

The protocol will assess the following outcomes:

  • The ultimate fate of this increased hepatic fatty acid production following a high fructose vs. glucose diet
  • The effect of a high fructose vs. glucose diet on liver ATP stores
  • The effect of a high fructose vs. glucose diet on markers of oxidative stress
  • The effect of a high fructose vs. glucose diet on cardiovascular status

Factors critical to carbohydrate metabolism such as systemic insulin resistance, body composition, energy expenditure, physical activity will also be assessed.

32 centrally overweight healthy males with a low baseline fructose intake will be recruited. They will be randomised double blindly to receive 25% of their dietary energy requirements from either fructose or glucose for 14 days.

The sugars will first be taken in an energy balanced and then an overfeeding setting.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index 25-32
  • Waist > hip circumference
  • Age 18-50 years
  • Male

Exclusion criteria

  • Reported weight change > 3 kg in prior 3/12
  • Active health problems
  • Contraindications to MRI scanning
  • Symptoms of functional bloating or irritable bowel syndrome
  • Abnormal liver or renal function tests
  • Random glucose greater than 11.0 mmol/L
  • Evidence of metabolic or viral liver disease as screened for by hepatitis B and C serology, and ferritin.
  • Alcohol intake > 21 units per week
  • Vegetarianism
  • Normal daily fructose intake from drinks greater than that in 500ml of coca cola
  • Abnormal carbohydrate energy contribution to baseline diet - defined as greater than 2 standard deviations from the mean of the National Diet and Nutrition Survey 2002 data

Treatment and study plan

high sugar diet

Dietary Supplement

25% of dietary energy from fructose or glucose

Primary outcomes

  1. Liver triglyceride content

    Time frame: 2 weeks

Secondary outcomes

  1. Muscle triglyceride content

    Time frame: 2 weeks

  2. Total abdominal visceral fat content (MRI)

    Time frame: 2 weeks

  3. Liver ATP, PME concentration and pH (31P MRS)

    Time frame: 2 weeks

  4. Liver de novo lipogenesis

    Time frame: 2 weeks

  5. Resting energy expenditure, lipid and carbohydrate oxidation rates

    Time frame: 2 weeks

  6. Hepatic and systemic insulin resistance

    Time frame: 2 weeks

  7. Cardiovascular measures using finometry

    Time frame: 2 weeks

  8. Systemic oxidative stress and inflammatory cytokine profile

    Time frame: 2 weeks

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2011
First posted
Jan 15, 2010
Registry last updated
Jul 4, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.